Abstract
Host polymorphisms in the IL28B region have recently been associated with outcome of treatment for hepatitis C virus (HCV) infection. This study clearly shows an association between first-phase viral load decrease and the IL28B rs12979860 polymorphism in chronic HCV-infected patients. Furthermore, a higher treatment efficiency factor (ɛ) was found in those HCV-infected patients with a CC genotype compared with those with a CT and TT genotype. This study highlights the importance of host response mechanisms in relation to favourable clearance of HCV.
Copyright © 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antiviral Agents / therapeutic use*
-
Hepacivirus / drug effects*
-
Hepacivirus / physiology
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / genetics*
-
Hepatitis C, Chronic / virology
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use
-
Interferons
-
Interleukins / genetics*
-
Polyethylene Glycols / therapeutic use
-
Polymorphism, Single Nucleotide / genetics*
-
Recombinant Proteins / therapeutic use
-
Ribavirin / therapeutic use
-
Treatment Outcome
-
Viral Load / drug effects*
Substances
-
Antiviral Agents
-
interferon-lambda, human
-
Interferon alpha-2
-
Interferon-alpha
-
Interleukins
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
Interferons
-
peginterferon alfa-2b